The A-share innovative drug sector continued to weaken, with Yuhang Pharmaceutical, Hansen Pharmaceutical, and Jiankai Technology hitting the daily limit down. Toujing Life and Wanbang Pharmaceutical fell by more than 10%, and Zhongguancun, Xidian Pharmaceutical, Qianjin Pharmaceutical, Pris, and Longshen Rongfa and other stocks followed suit.